U.S. markets closed
  • S&P 500

    4,655.27
    +60.65 (+1.32%)
     
  • Dow 30

    35,135.94
    +236.60 (+0.68%)
     
  • Nasdaq

    15,782.83
    +291.18 (+1.88%)
     
  • Russell 2000

    2,241.98
    -3.96 (-0.18%)
     
  • Crude Oil

    70.59
    +0.64 (+0.91%)
     
  • Gold

    1,788.80
    +3.60 (+0.20%)
     
  • Silver

    22.96
    +0.11 (+0.47%)
     
  • EUR/USD

    1.1298
    -0.0022 (-0.19%)
     
  • 10-Yr Bond

    1.5300
    +0.0480 (+3.24%)
     
  • GBP/USD

    1.3316
    -0.0023 (-0.17%)
     
  • USD/JPY

    113.8070
    +0.4970 (+0.44%)
     
  • BTC-USD

    57,816.07
    +686.32 (+1.20%)
     
  • CMC Crypto 200

    1,460.81
    +31.88 (+2.23%)
     
  • FTSE 100

    7,109.95
    +65.92 (+0.94%)
     
  • Nikkei 225

    28,283.92
    -467.70 (-1.63%)
     

Nektar Therapeutics: Q4 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Nektar Therapeutics (NASDAQ:NKTR) moved higher in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share were down 1.56% over the past year to ($0.65), which beat the estimate of ($0.68).

Revenue of $23,462,000 declined by 30.71% from the same period last year, which missed the estimate of $30,010,000.

Outlook

Nektar Therapeutics hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Feb 25, 2021

View more earnings on NKTR

Time: 05:00 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/t22se9js

Recent Stock Performance

52-week high: $26.75

52-week low: $13.63

Price action over last quarter: Up 30.88%

Company Overview

Nektar Therapeutics is a San Francisco-based emerging biotechnology company specializing in PEGylation technology. Its portfolio includes PEGylated biologics in immuno-oncology, breast cancer, and autoimmune disease. The company partners with several large pharmaceutical and biotechnology companies to co-develop therapies in a range of indications, which includes a collaboration with Bristol-Myers Squibb to develop bempegaldesleukin, the firm's leading immuno-oncology candidate, in combination with Bristol's Opdivo.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.